Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Status:
Withdrawn
Trial end date:
2017-09-13
Target enrollment:
Participant gender:
Summary
This clinical investigation is a substudy within GS-US-416-2124, IND 129570, which is A Phase
2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of
GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe
Alcoholic Hepatitis. The use of the HepQuant SHUNT test is to assess liver disease severity
before, during, and after treatment with GS-4997 or placebo, to assess liver disease
severity.